TY - JOUR
AR - SCR-2024-2-101
TI - Splenectomy before Allogeneic Hematopoietic Stem-cell Transplantation for Myelofibrosis: Two Cases
AU - Zhengxiang, Yang
AU - Aibin, Zhang
AU - Xiaoyu, Lai
AU - Luxin, Yang
AU - Yishan, Ye
AU - Qingna, Guo
AU - Yibo, Wu
AU - He, Huang
AU - Yi, Luo
AU - Lizhen, Liu
JO - Surgical Case Reports
PY - 2024
DA - Tue 30, Jul 2024
SN - 2613-5965
DO - http://dx.doi.org/10.31487/j.SCR.2024.02.01
UR - https://www.sciencerepository.org/splenectomy-before-allogeneic-hematopoietic_SCR-2024-2-101 
KW - Splenectomy, myelofibrosis, massive splenomegaly, allogeneic hematopoietic stem cell transplantation
AB - Myelofibrosis (MF) is a clonal hematological malignancy characterized by splenomegaly, systemic symptoms, myelofibrosis, and a tendency to transform into acute leukemia. MF treatment includes anemia treatment, hydroxyurea, JAK inhibitors (JAKi) allogeneic hematopoietic stem cell transplantation (allo-HSCT), among which allo-HSCT is the only possible cure for MF. The effect of splenomegaly on the prognosis of allo-HSCT with myelofibrosis and whether splenic treatment is needed before transplantation has not been determined. A recent retrospective study from the EBMT working group found that splenectomy significantly reduced transplant-related non-recurrent mortality and did not increase the risk of disease recurrence in MF patients with pre-transplant splenomegaly. Two cases of MF splenectomy combined with allo-HSCT are reported.